Allergies: Medical Treatments
(asked on 20th May 2026) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has considered exempting information on how to use adrenaline devices from restrictions only allowing medical professionals to access information about prescription medicines.
Following the approval of an adrenaline nasal spray by the Medicines and Healthcare products Regulatory Agency (MHRA) in July 2025, the Government is considering whether any amendments to Schedule 17 of the Human Medicines Regulations 2012 are appropriate. Any changes to access arrangements would represent an amendment to the current regulatory framework and would require consideration of patient safety and appropriate clinical use. Should changes be proposed, a public consultation would be undertaken.
The National Institute of Health and Care Excellence (NICE) has been notified of the considerations being made by the Department in this area. NICE is not currently considering producing guidance on EURneffy. NICE will continue to monitor new evidence on this topic, in line with its usual processes. NICE has met with the National Institute for Health and Care Research which has agreed to explore whether research on this topic would be feasible and, if so, what research programme it might be suited to.
There are no restrictions on accessing information on how to use adrenaline devices, whether by a medical professional or member of the public. Guidance from the MHRA on their website and on YouTube includes information on the correct use of adrenaline auto-injectors and what to do in an emergency, with further information available at the following two links:
https://www.youtube.com/watch?v=4vNR5N1-iBw
The manufacturers of adrenaline devices also provide a range of training materials freely available to the public, including training devices without medication, guides on instructions for use, and video demonstrations.